Extended Follow-Up from JAVELIN Renal 101: Subgroup Analysis of Avelumab Plus Axitinib Versus Sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium Risk Group in Patients with Advanced Renal Cell Carcinoma.
ESMO OPEN（2023）
Key words
renal cell carcinoma,risk factor,avelumab,immunotherapy,phase III
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined